Literature DB >> 23700206

Acute mucosal reactions in patients with head and neck cancer. Three patterns of mucositis observed during radiotherapy.

A Wygoda1, T Rutkowski, M Hutnik, K Składowski, M Goleń, B Pilecki.   

Abstract

PURPOSE: To investigate the individual pattern of acute mucosal radiation reactions (AMRR) in patients with head and neck cancer who were treated with radiotherapy alone. Reactions were evaluated daily on an individual basis according to the Dische scoring system.
MATERIALS AND METHODS: Treatment of 87 head and neck cancer patients comprised either conventional fractionation- (CF; n = 33), accelerated fractionation (AF; n = 33), hyperfractionated- (HPEFX; n = 12) or hypofractionated (HPOFX; n = 9) radiotherapy with radical intent. Daily evaluation of AMRR progression was performed prospectively using a modified, morphologically functional Dische scoring system. The daily sums of the score parameters were subsequently used to construct an individual AMRR course curve for each patient.
RESULTS: A latency period ranging from 3 to 14 days between the start of radiotherapy and the occurrence of the first AMRR symptom was observed in all patients. Based on the three different shapes of AMRR course curve observed during radiotherapy, three types of AMRR course can be described: (1) a continual increase in AMRR intensity until the completion of radiotherapy; (2) the incidence of a plateau phase following the increase in AMRR (increase-plateau course) and (3) decreasing AMRR intensity with a healing phase. A continual increase in AMRR intensity was observed in about 25 % of CF and AF patients and in more than 50 % of HPOFX treatments. This type of reaction was not observed in the HPEFX group. The increase-plateau course was noted in the majority of AF and CF patients; in almost half of those treated with HPOFX and in all HPEFX patients. A decreasing AMRR intensity course was observed in 23 % of all patients, although not observed at all in the HPEFX and HPOFX fractionation groups.
CONCLUSION: The course of AMRR during radiotherapy can differ between individual patients. After the initial increase in AMRR intensity, a stabilization of the reaction--visible as a plateau phase on the course curve--is observed in the majority of patients. A proportion of the irradiated patients experience a continual increase in AMRR intensity up until the end of radiotherapy. A further group of patients exists in whom signs of AMRR healing are observed during the final stages of radiotherapy.

Entities:  

Mesh:

Year:  2013        PMID: 23700206     DOI: 10.1007/s00066-013-0311-8

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  21 in total

1.  Accelerated radiation therapy, seven fractions per week, for advanced head and neck cancer--a feasibility study.

Authors:  Joe M O'Sullivan; Donal P Hollywood; Nuala Cody; Joe Dillon; Steve Buckney; Michael J Moriarty; John G Armstrong
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-06       Impact factor: 4.126

2.  Definitive radiochemotherapy of advanced head and neck cancer with carboplatin and paclitaxel : a phase II study.

Authors:  Robert Semrau; Susanne Temming; Simon Florian Preuss; Jens Peter Klubmann; Orlando Guntinas-Lichius; Rolf-Peter Müller
Journal:  Strahlenther Onkol       Date:  2011-09-23       Impact factor: 3.621

3.  Continuous accelerated 7-days-a-week radiotherapy for head-and-neck cancer: long-term results of phase III clinical trial.

Authors:  Krzysztof Skladowski; Boguslaw Maciejewski; Maria Golen; Rafal Tarnawski; Krzysztof Slosarek; Rafal Suwinski; Mariusz Sygula; Andrzej Wygoda
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

4.  High-grade acute organ toxicity as positive prognostic factor in primary radio(chemo)therapy for locally advanced, inoperable head and neck cancer.

Authors:  Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

Review 5.  Altered fractionation: limited by mucosal reactions?

Authors:  J H Kaanders; A J van der Kogel; K K Ang
Journal:  Radiother Oncol       Date:  1999-03       Impact factor: 6.280

6.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.

Authors:  K K Fu; T F Pajak; A Trotti; C U Jones; S A Spencer; T L Phillips; A S Garden; J A Ridge; J S Cooper; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-08-01       Impact factor: 7.038

7.  Accelerated radiotherapy with delayed concomitant boost in locally advanced squamous cell carcinoma of the head and neck.

Authors:  R MacKenzie; J Balogh; R Choo; E Franssen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-10-01       Impact factor: 7.038

Review 8.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.

Authors:  Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg
Journal:  Radiother Oncol       Date:  2003-03       Impact factor: 6.280

9.  Accelerated fractionation radiotherapy for laryngeal cancer, acute, and late toxicity.

Authors:  J H Kaanders; W A van Daal; W J Hoogenraad; A J van der Kogel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

10.  Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation.

Authors:  B Maciejewski; H R Withers; J M Taylor; A Hliniak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1989-03       Impact factor: 7.038

View more
  11 in total

1.  Effects of bone marrow or mesenchymal stem cell transplantation on oral mucositis (mouse) induced by fractionated irradiation.

Authors:  M Schmidt; J Haagen; R Noack; A Siegemund; P Gabriel; W Dörr
Journal:  Strahlenther Onkol       Date:  2014-01-24       Impact factor: 3.621

2.  Radiation recall dermatitis after docetaxel chemotherapy. Treatment by antioxidant ointment.

Authors:  Viola Duncker-Rohr; Ulrich Freund; Felix Momm
Journal:  Strahlenther Onkol       Date:  2014-03-11       Impact factor: 3.621

3.  8-prenylnaringenin and tamoxifen inhibit the shedding of irradiated epithelial cells and increase the latency period of radiation-induced oral mucositis : cell culture and murine model.

Authors:  Tine De Ryck; Annouchka Van Impe; Barbara W Vanhoecke; Arne Heyerick; Luc Vakaet; Wilfried De Neve; Doreen Müller; Margret Schmidt; Wolfgang Dörr; Marc E Bracke
Journal:  Strahlenther Onkol       Date:  2014-11-29       Impact factor: 3.621

4.  Modulation of radiation-induced oral mucositis by pentoxifylline: preclinical studies.

Authors:  Sylvia Gruber; Margret Schmidt; Eva Bozsaky; Kathrin Wolfram; Julia Haagen; Bettina Habelt; Martin Puttrich; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2014-10-29       Impact factor: 3.621

5.  Duration of acute esophageal toxicity in concomitant radio-chemotherapy for non-small cell lung cancer with different fractionation schedules.

Authors:  Joanna Socha; Ewa Wasilewska-Teśluk; Rafal Stando; Lukasz Kuncman; Lucyna Kepka
Journal:  Br J Radiol       Date:  2021-09-24       Impact factor: 3.039

Review 6.  Pathophysiology of Radiation-Induced Dysphagia in Head and Neck Cancer.

Authors:  Suzanne N King; Neal E Dunlap; Paul A Tennant; Teresa Pitts
Journal:  Dysphagia       Date:  2016-04-20       Impact factor: 3.438

7.  Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy.

Authors:  Matthias F Haefner; Kristin Lang; David Krug; Stefan A Koerber; Lorenz Uhlmann; Meinhard Kieser; Juergen Debus; Florian Sterzing
Journal:  J Radiat Res       Date:  2015-04-23       Impact factor: 2.724

8.  Early inflammatory changes in radiation-induced oral mucositis : Effect of pentoxifylline in a mouse model.

Authors:  Sylvia Gruber; Eva Bozsaky; Eva Roitinger; Karoline Schwarz; Margret Schmidt; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2017-03-03       Impact factor: 3.621

9.  Protective effects of systemic dermatan sulfate treatment in a preclinical model of radiation-induced oral mucositis.

Authors:  Sylvia Gruber; Katharina Frings; Peter Kuess; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2018-03-01       Impact factor: 3.621

10.  Radioprotection of targeted and bystander cells by methylproamine.

Authors:  Susanne Burdak-Rothkamm; Andrea Smith; Pavel Lobachevsky; Roger Martin; Kevin M Prise
Journal:  Strahlenther Onkol       Date:  2014-09-23       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.